Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giredestrant plus Phesgo versus Phesgo maintenance after taxane induction in untreated HER2-positive/ER-positive advanced breast cancer
CTR20221625Phase 3Active
- Sponsor
- Roche
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of giredestrant, trastuzumab in breast cancer, sponsored by Roche. Started Jun 2022; status: active.
02
Drugs
giredestranttrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20221625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221625.